Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
复制标题
DOI：
10.1056/nejmoa051688
复制
发表时间：
2005-09-22
影响因子：
158.5
通讯作者：
Hsiao, JK
中科院分区：
文献类型：
--
作者：
Lieberman, JA;Stroup, TS;Hsiao, JK
背景：第二代（非典型）抗精神病药物与较老药物相比的相对有效性尚未完全解决，尽管目前较新药物的使用更为普遍。我们比较了第一代抗精神病药，奋乃静，与几个新的药物在一个双盲study.METHODS：共1493例精神分裂症患者被招募在57个美国网站和随机分配到奥氮平（7.5至30毫克每天），奋乃静（8至32毫克每天），奎替鲁胺（200至800毫克每天），或利培酮（1.5至6.0毫克每天）长达18个月。齐拉西酮（每天40至160毫克）在获得食品和药物管理局批准后被纳入。主要目的是描绘这五个treatment.Results的总体疗效的差异：总体而言，74%的患者停止研究药物前18个月（1061 1432例患者谁收到至少一个剂量）：64%的人分配到奥氮平，75%的人分配到奋乃静，82%的人分配到奎替鲁，74%的人分配到利培酮，和79%的人分配到齐拉西酮。奥氮平组至因任何原因停止治疗的时间显著长于奎替尼组（P
BACKGROUND:The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study.METHODS:A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments.RESULTS:Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P